
Financial Report 2022

Stichting voor Lever en Maag-Darm
Onderzoek

At ROTTERDAM, The Netherlands



216 Accountants B.V.
Breda, 23 June 2023
This report includes 31 pages
02060-23HG413

Table of contents

Compilation statement	3
Report of the board for the year 2022.....	4
Balance sheet as at 31 December 2022	5
Statement of income and expenditure 2022.....	6
Notes to the annual accounts 2022	7
ANNEXES	
A. Publications relased in 2022	14
B. Promotions in 2022	32
C. Events organized in 2022	33

Compilation Statement

The financial statements of Stichting voor Lever en Maag-Darm Onderzoek based in Rotterdam have been compiled by us using the information provided by you. The financial statements comprise the balance sheet as at 31 December 2022 and the statement of income and expenditure for the year 2022, with the accompanying explanatory notes. These notes include a summary of the accounting policies which have been applied.

This compilation engagement has been performed by us in accordance with Dutch law, including the Dutch Standard 4410, 'Compilation engagements', which is applicable to accountants. The standard requires us to assist you in the preparation and presentation of the financial statements in accordance with accounting principles as determined by the board of the foundation. To this end we have applied our professional expertise in accounting and financial reporting.

In a compilation engagement, you are responsible for ensuring that you provide us with all relevant information and that this information is correct. Therefore, we have conducted our work, in accordance with the applicable regulations, on the assumption that you have fulfilled your responsibility. To conclude our work, we have read the financial statements as a whole to consider whether the financial statements as presented correspond with our understanding of Stichting voor Lever en Maag-Darm Onderzoek.

We have not performed any audit or review procedures which would enable us to express an opinion or a conclusion as to the fair presentation of the financial statements.

During this engagement we have complied with the relevant ethical requirements prescribed by the 'Verordening Gedrags- en Beroepsregels Accountants' (VGBA, Dutch Code of Ethics). You and other users of these financial statements may therefore assume that we have conducted the engagement in a professional, competent and objective manner and with due care and integrity and that we will treat all information provided to us as confidential.

For further information on the nature and scope of a compilation engagement and the VGBA we refer you to www.nba.nl/uitleg-samenstellingsverklaring.

Breda, 23rd June 2023

216 Accountants B.V.



H. Göksu AA

Reference number: **02060-23HG413**

Internal reference: 1000002060

Report of the board for the year 2022

Rotterdam, 23th June 2023

Aim of the Foundation is to promote scientific research of gastrointestinal and liver disorders.

In 2022, the Foundation continued the research projects that were reinstated in 2021, after it was interrupted due to the COVID -19 pandemic in 2020, and new research projects have been started. In 2022 new projects amounted to EUR 2.140.000. For 2023, we expect a similar awarded amount or the amount may even increase.

In 2022 there were no changes in the Executive Board of the Foundation. Prof.dr. H.L.A. Janssen has joined as one of the board members as a cluster leader. He has been working at the University of Toronto, Canada for several years, and returned to the department of Gastroenterology & Hepatology in the beginning of 2022. In 2023 he will be the director of the Gastroenterology & Hepatology department of the Erasmus University Medical Center. Dr. A. de Vries has taken over the board membership from prof.dr. J. van der Woude and is now managing her cluster. In 2022, the board of the Foundation consisted of 11 members, each with their own cluster.

A number of personnel changes within the Clinical Trial Bureau were announced at the end of 2022: both the coordinator and one of the research nurses decided to take up positions elsewhere. To ensure smooth continuation of all ongoing and new clinical projects, new staff will be recruited in 2023, and special attention will be given to make the workflow of all projects as efficient as possible to allow initiation and continuation of all clinical studies offered to the Foundation.

A total of 188 peer reviewed articles have been published in international articles and 12 PhD students have finished their thesis in 2022. The Foundation has played a key role in this success.

In 2022, the 37th Erasmus Liver Day took place. A total of 288 participants attended the meeting. In contrast to the Erasmus Liver Day in 2020 and 2021 it was now fully physical, not hybrid, and took place at the conference center De Doelen, as in pre-Covid times.

The Foundation is a financially healthy Foundation with ANBI-status. The Foundation will continue to invest in translational and clinical research of gastrointestinal and liver disorders. In order to provide optimal transparency of the Foundation's finances and activities, the website (www.slofoundation.nl) is continuously updated and provides the latest information relevant for professionals and public.

The Board wants to express their gratitude to the Supervisory Board for their input and advice.

Manon Spaander, Chairman
Rob de Knecht, Treasurer
Andre Boonstra, Secretary

Balance sheet as at 31 December 2022

(after appropriation of result)

	2022	2021
	€	€
Assets		
Current assets		
Research projects	4.704.264	4.843.515
Instalments on research projects	-6.691.625	-7.400.129
Accounts receivable	247.910	219.554
Cash at bank and in hand	3.069.018	3.555.847
Other receivables	159.404	-
	1.430.622	1.218.787
Current liabilities	-254.708	-321.236
Working Capital	<u>1.117.565</u>	<u>897.551</u>
Foundation Equity	1.117.565	897.551

Statement of income and expenditure 2022

	<u>2022</u>	<u>2021</u>
	€	€
Revenue from investigations	1.644.392	1.841.231
Other income	-	-
Investigate change in capitalized costs in progress	569.253	104.058
Sum of revenues	2.213.645	1.945.289
Investigate direct costs	1.787.557	1.687.541
General expenses:		
- Personnel costs	122.007	181.544
- Other operating costs	74.502	84.979
Sum of costs	<u>-1.984.066</u>	<u>-1.954.064</u>
Operating result before interest	229.579	-8.775
Financial income and expenses	<u>-9.565</u>	<u>-13.976</u>
Net result	220.014	-22.751

Notes to the annual accounts 2022

Principles of valuation and determination of the result

ANBI status

The Foundation for Liver Gastrointestinal Research has its registered office at 3065RD Rotterdam, Kralingsweg 369.

The Foundation aims to:

- a) promoting scientific research in the field of gastrointestinal and liver diseases, including diseases of the bile ducts, pancreas and oesophagus;
- b) promoting an adequate infrastructure for the specialism of Gastrointestinal and Liver Diseases and related surgery, mainly in the Erasmus MC and the Rotterdam region.

The Foundation has included in the ANBI register at the Dutch tax authorities

General

The annual accounts are drawn up on the basis of the accounting principles as chosen by the board of the foundation.

Tangible fixed assets are charged to a project directly or to the statement of income and expenditure.

Unless stated otherwise, all assets and liabilities are stated at nominal value.

Receivables and short-term debts are receivables and debts due within one year.

Research projects in progress

These are valued at attributable costs of third parties, attributable personnel costs and a surcharge for indirect costs.

In case of an expected loss on a research project, a provision is formed for the entire amount of the expected loss.

Operating result

The results on research projects (contributions and donations minus costs attributable to them) are recognized in the statement of income and expenditure according to the percentage of completion method. The revenue from research projects consists of contributions received on the completed projects, less revenues which have already been accounted for in previous years.

Taking into account of these accounting principles, the operating result is determined as the difference between research revenues and attributable costs and other income and expenses in the year, determined on the basis of historical costs.

Balance as at 31 December 2022

Current assets

Research projects in progress

	2022 EUR	2021 EUR
Costs projects in progress	6.134.083	6.010.402
Less: Provision for foreseen losses on projects	-1.429.819	-1.166.887
	<u>4.704.264</u>	<u>4.843.515</u>

The movements in the Costs projects in progress during the year can be specified as follows:

	2022 EUR	2021 EUR
Balance as at January 1	6.010.402	5.333.755
Research expenses:		
Personnel costs	1.340.987	1.154.166
External research agencies	37.630	19.146
Laboratory costs	51.403	145.270
Travel expenses	86.017	23.817
Conferences	65.044	54.759
Phone/Internet	14.143	10.156
Purchase equipment	2.877	7.252
Legal support	15.348	-
METC costs	40.508	61.309
Cost of bad debts	-	-
Miscellaneous expenses	133.600	211.666
	<u>1.787.557</u>	<u>1.687.541</u>
Allocated overhead expenses	<u>215.223</u>	<u>202.507</u>
	<u>2.002.780</u>	<u>1.890.048</u>
	<u>8.013.182</u>	<u>7.223.803</u>
Completed research projects	<u>-1.878.379</u>	<u>-1.213.401</u>
Balance as at December 31	6.134.803	6.010.402

Instalments on projects

This concerns instalments received from clients with respect to research projects that have not yet been completed. These amounts are released to the statement of income and expenditure under the heading "Revenue from research projects", according to the percentage of completion of the research project.

	2022 EUR	2021 EUR
Invoiced instalments	7.497.778	7.830.561
Released due to statement of income and expenditure	-806.153	-430.432
	<u>6.691.625</u>	<u>7.400.129</u>

The movements in the Invoiced instalments during the year can be specified as follows:

	2022 EUR	2021 EUR
<i>Balance as at January 1</i>		
Invoiced instalments	7.830.561	7.319.027
Released to statement of income and expenditure	-430.432	-362.946
	<u>7.400.129</u>	<u>6.956.081</u>

	2022 EUR	2021 EUR
<i>Movements in the financial year</i>		
Invoiced instalments	1.644.392	1.841.231
Completed research projects	-1.977.175	-1.329.697
To statement of income and expenditure	-375.721	-67.486
	<u>-708.504</u>	<u>444.048</u>

	2022 EUR	2021 EUR
Balance as at December 31		
Invoiced instalments	7.497.778	7.830.561
Released to statement of income and expenditure	-806.153	-430.432
	<u>6.691.625</u>	<u>7.400.129</u>

Receivables and accruals

	2022	2021
	EUR	EUR
Debtors	247.910	219.554

Liquid assets

	2022	2021
	EUR	EUR
ABN AMRO, Current account	7.060	10.674
ABN AMRO, Capital market index account	200.674	200.674
ABN AMRO, Bonus savings account	973.405	988.405
ABN AMRO, Business deposit	952.702	952.702
ABN AMRO, Support account	-	989
Rabobank, Current account	189.910	654.277
Rabobank, Savings account	745.267	748.126
	3.069.018	3.555.847

Other receivables

	2022	2021
	EUR	EUR
Amounts still to be received	74.924	-
Accrued expenses	26.131	-
Staff costs to be paid	58.349	-
	159.404	-

Current liabilities

	2022	2021
	EUR	EUR
Creditors	327.245	118.311
Accrued expenses	-	192.812
VAT	44.161	10.113
	254.708	321.236

Foundation equity

	2022	2021
	EUR	EUR
Balance as at January 1	897.551	920.302
Result for the year	220.014	-22.751
Balance as at December 31	<u>1.117.565</u>	<u>897.551</u>

The foundation's equity consists of a General Reserve and cluster reserves related to active clusters within the foundation. The cluster reserves are at disposal of the respective clusters to be used autonomously for the costs of research projects to be initiated within the clusters. The positive or negative results of a year are allocated to the cluster's reserves as follows:

The movement of the cluster reserve is determined annually on the basis of the total of the positive or negative balances of the research projects within the cluster and consists partly of the General reserve of the Foundation's equity from the deficit/surplus on the allocated overhead expenses to projects.

The movements in 2022 are as follows:

	As at	Movements	As at
	January 1	EUR	December 31
	EUR	EUR	EUR
General	206.841	8.434	215.275
Cluster 1	43.774	-1.599	42.175
Cluster 2	-	197	197
Cluster 3	94.613	-48.713	45.900
Cluster 4	5.553	140.602	146.155
Cluster 5	114.915	-15.748	99.165
Cluster 6	196.446	-37.044	159.402
Cluster 7	1.970	207.320	209.290
Cluster 8	153.321	16.888	170.209
Cluster 9	189	3.354	3.543
Cluster 10	79.929	-47.248	32.681
Cluster 11	-	-6.427	-6.427
	<u>897.551</u>	<u>220.014</u>	<u>1.117.565</u>

Statement of income and expenses 2022

Direct costs

	2022	2021
	EUR	EUR
Personnel expenses	1.340.987	1.154.166
External research agencies	37.630	19.146
Laboratory expenses	51.403	145.270
Travel expenses	86.017	23.817
Conferences	65.044	54.759
Phone/Internet	14.143	10.156
Purchase equipment	2.877	7.252
Legal support	15.348	-
METC costs	40.508	61.309
Miscellaneous expenses	133.600	211.666
	<u>1.787.557</u>	<u>1.687.541</u>

The personnel expenses are charged by Erasmus MC for personnel that has been deployed to research projects.

Travel expenses

	2022	2021
	EUR	EUR
Study-related travel expenses	13.431	13.676
Travel expenses for professors for recruitment of new studies	16.850	1.766
Travel expenses for staff members to attend conferences and presentation of the result studies	55.736	8.375
	<u>86.017</u>	<u>23.817</u>

General expenses

Personnel expenses

	2022	2021
	EUR	EUR
Personnel expenses - indirect	118.629	180.401
Travel expenses	2.675	1.049
Canteen costs	703	94
	<u>122.007</u>	<u>181.544</u>

The personnel expenses are charged by Erasmus MC for personnel of the Clinical Research Bureau, which performs support and administrative tasks.

Other operating costs

	2022	2021
	EUR	EUR
Accounting expenses	60.000	60.000
Accountant fees	2.850	3.300
Other general expenses	11.652	21.679
	<hr/> 74.502	<hr/> 84.979

Financial income and expenses

	EUR	EUR
Interest expenses	<hr/> -9.565	<hr/> -13.976

A Publications released in 2022

1. Aggarwal A, Montanari NR, Ramirez R, Diehl L, Feierbach B, Boonstra A. Reply to: "Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection". *J Hepatol.* 2022;77(5):1457.
2. Aronson SJ, Junge N, Trabelsi M, Kelmami W, Hubert A, Brigatti KW, Fox MD, de Knecht RJ, Escher JC, Ginocchio VM, Iorio R, Zhu Y, Ozcay F, Rahim F, El-Shabrawi MHF, Shteyer E, Di Giorgio A, D'Antiga L, Mingozzi F, Brunetti-Pierri N, Strauss KA, Labrune P, Mrad R, Baumann U, Beuers U, Bosma PJ, Cure CNC. Disease burden and management of Crigler-Najjar syndrome: Report of a world registry. *Liver Int.* 2022;42(7):1593-604.
3. Arkenbosch JHC, Beelen EMJ, Dijkstra G, Romberg-Camps M, Duijvestein M, Hoentjen F, van der Marel S, Maljaars PWJ, Jansen S, de Boer NKH, West RL, Horjus CS, Stassen LPS, van Schaik FDM, van Ruler O, Jharap BJH, Visschedijk M, Janssen A, Erler NS, Doukas M, Ooms A, Kats-Ugurlu G, van der Woude CJ, de Vries AC, Dutch Initiative on Cs, Colitis. Prophylactic medication for the prevention of endoscopic recurrence in Crohn's disease: a prospective study based on clinical risk stratification. *J Crohns Colitis.* 2022.
4. Arkenbosch JHC, van Ruler O, Dwarkasing RS, Fuhler GM, Schouten WR, van Oud-Alblas MB, de Graaf EJR, de Vries AC, van der Woude CJ. Stromal vascular fraction with platelet-rich plasma injection during surgery is feasible and safe in treatment-refractory perianal fistulising Crohn's disease: A pilot study. *Aliment Pharmacol Ther.* 2022.
5. Arkenbosch JHC, Mak JWY, Ho JCL, Beelen EMJ, Erler NS, Hoentjen F, Bodelier AGL, Dijkstra G, Romberg-Camps M, de Boer NKH, Stassen LPS, van der Meulen AE, West R, van Ruler O, van der Woude CJ, Ng SC, de Vries AC. Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West. *Inflamm Bowel Dis.* 2022 Jun 2;28(Suppl 2):S16-S24.
6. Ayada I, van Kleef LA, Alferink LJM, Li P, de Knecht RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. *Liver Int.* 2022;42(2):277-87.
7. Bak MTJ, Albeniz E, East JE, Coelho-Prabhu N, Suzuki N, Saito Y, Matsumoto T, Banerjee R, Kaminski MF, Kiesslich R, Coron E, de Vries AC, van der Woude CJ, Bisschops R, Hart AL, Itzkowitz SH, Pioche M, Moons LMG, Oldenburg B. Endoscopic management of patients with high-risk colorectal colitis-associated neoplasia: a Delphi study. *Gastrointest Endosc.* 2022.
8. Bak MTJ, Ruitkamp MFE, van Ruler O, Campmans-Kuijpers MJE, Bongers BC, van Meeteren NLU, van der Woude CJ, Stassen LPS, de Vries AC. Prehabilitation prior to intestinal resection in Crohn's disease patients: An opinion review. *World J Gastroenterol.* 2022 Jun 14;28(22):2403-2416.
9. Beudeker BJB, Groothuisink ZMA, van der Eijk AA, Debes JD, Boonstra A. Circulating Cytokines Reflect the Etiology-Specific Immune Environment in Cirrhosis and HCC. *Cancers (Basel).* 2022;14(19).
10. Beumer BR, Buettner S, Galjart B, van Vugt JLA, de Man RA, JNM IJ, Koerkamp BG. Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. *Eur J Surg Oncol.* 2022;48(3):492-9.
11. Beumer BR, Polak WG, de Man RA, Metselaar HJ, van Klaveren D, Labrecque J, IJzermans JN. Impact of waiting time on post-transplant survival for recipients with hepatocellular carcinoma: A natural experiment randomized by blood group. *JHEP Rep.* 2022 Nov 22;5(2):100629.

12. Blauw JTM, Metz FM, Brusse-Keizer M, Rijnja P, Bruno MJ, Geelkerken RH; Dutch Mesenteric Ischaemia Study Group. Coeliac Artery Release or Sham Operation in Patients Suspected of Having Median Arcuate Ligament Syndrome: The CARoSO study. *Eur J Vasc Endovasc Surg.* 2022 Nov;64(5):573-574.
13. Bouzid R, Kessler AL, Levink IJM, van den Bosch TPP, Buschow SI, Fuhler GM, Peppelenbosch MP, Cros J, Lévy P, Bruno MJ, Doukas M. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen-Letter. *Clin Cancer Res.* 2022 Jan 15;28(2):425-426.
14. Biewenga M, Heidt S, Vergunst M, Marijnissen CMJ, de Man RA, van der Eijk AA, van der Meer AJ, Trouw LA, van Hoek B. B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. *JHEP Rep.* 2022;4(5):100460.
15. Braal CL, de Knecht RJ, Jager A, Koolen SLW, Mathijssen RHJ, Eechoute K. Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation. *Hepatol Commun.* 2022;6(9):2565-8.
16. Brakenhoff SM, de Knecht RJ, Oliveira J, van der Eijk AA, van Vuuren AJ, Hansen BE, Janssen HLA, de Man RA, Boonstra A, Sonneveld MJ. Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B. *J Infect Dis.* 2022;227(1):113-22.
17. Breekveldt ECH, Lansdorp-Vogelaar I, Toes-Zoutendijk E, Spaander MCW, van Vuuren AJ, van Kemenade FJ, Ramakers CRB, Dekker E, Nagtegaal ID, Krul MF, Kok NFM, Kuhlmann KFD, Vink GR, van Leerdam ME, Elferink MAG, Dutch National Colorectal Cancer Screening Working G. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. *Lancet Gastroenterol Hepatol.* 2022;7(1):60-8.
18. Bruno MJ. Main duct intraductal papillary mucinous neoplasm: resect or not resect, that is the question. *Gastrointest Endosc.* 2022 Feb;95(2):297-298.
19. Buskermolen M, Naber SK, Toes-Zoutendijk E, van der Meulen MP, van Grevenstein WMU, van Leerdam ME, Spaander MCW, Lansdorp-Vogelaar I. Correction: Impact of surgical versus endoscopic management of complex nonmalignant polyps in a colorectal cancer screening program. *Endoscopy.* 2022;54(9):C14.
20. Choi HSJ, Hirode G, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong GLH, Brakenhoff SM, Chien RN, Feld JJ, Sonneveld MJ, Chan HLY, Fornis X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA, group R-Bs. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B. *Clin Gastroenterol Hepatol.* 2022.
21. Campos ST, Bruno MJ. Endoscopic Papillectomy. *Gastrointest Endosc Clin N Am.* 2022 Jul;32(3):545-562.
22. CORE-IBD Collaborators; Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Geary RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW, Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyszyn B, Yamamoto T, Allez

- M, Bemelman WA, Lightner AL, Louis E, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. *Gastroenterology*. 2022 Oct;163(4):950-964.
23. de Beijer MTA, Bezstarosti K, Luijten R, Doff WAS, Boor PPC, Pieterman RFA, Bouzid R, Biesta PJ, Ijzermans JNM, Doukas M, de Man RA, Woltman AM, Demmers JAA, Buschow SI. Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma. *JHEP Rep*. 2022;4(11):100576.
24. de Jonge L, van de Schootbrugge-Vandermeer HJ, Breekveldt ECH, Spaander MCW, van Vuuren HJ, van Kemenade FJ, Dekker E, Nagtegaal ID, van Leerdam ME, Lansdorp-Vogelaar I. Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic. *PLoS One*. 2022;17(6):e0270223.
25. de Jong DM, Fritzsche JA, Audhoe AS, Yi SSL, Bruno MJ, Voermans RP, van Driel LMJW. Comparison of Intraductal RFA Plus Stent versus Stent-Only Treatment for Unresectable Perihilar Cholangiocarcinoma-A Systematic Review and Meta- Analysis. *Cancers (Basel)*. 2022 Apr 21;14(9):2079.
26. de Veer RC, Harms MH, Corpechot C, Thorburn D, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Pares A, Mason AL, Kowdley KV, Trivedi PJ, Hirschfield GM, Brunts T, Dalekos GN, Gatselis NK, Verhelst X, Lammers WJ, Hansen BE, van Buuren HR, van der Meer AJ, Global PBCSG. Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid. *Aliment Pharmacol Ther*. 2022;56(9):1408-18.
27. de Veer RC, van Hooff MC, Corpechot C, Thorburn D, Invernizzi P, Lammers WJ, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Pares A, Mason AL, Kowdley KV, Trivedi PJ, Hirschfield GM, Goet JC, Brunts T, Dalekos GN, Gatselis NK, Verhelst X, Hansen BE, Harms MH, van der Meer AJ. Ursodeoxycholic acid treatment-induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis. *Am J Gastroenterol*. 2022.
28. Didden P, van Eijck van Heslinga RAH, Schwartz MP, Arensman LR, Vleggaar FP, de Graaf W, Koch AD, Doukas M, Lacle MM, Moons LMG. Relevance of polyp size for primary endoscopic full-thickness resection of suspected T1 colorectal cancers. *Endoscopy*. 2022 Nov;54(11):1062-1070.
29. Duizendstra AA, de Knecht RJ, Mancham S, Klepper M, Roelen DL, Brand-Schaaf SH, Boor PP, Doukas M, de Man RA, Sprengers D, Peppelenbosch MP, Betjes MGH, Kwekkeboom J, Litjens NHR. Activated CD4(+) T Cells and Highly Differentiated Alloreactive CD4(+) T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients. *Liver Transpl*. 2022;28(1):98-112.
30. Duizendstra AA, De Knecht RJ, Nagtzaam NMA, Betjes MGH, Dik WA, Litjens NHR, Kwekkeboom J. Minimal Development of Liver Fibrosis in Adult Tolerant Liver Transplant Recipients Late After Immunosuppressive Drug Weaning and Transplantation. *Transplant Proc*. 2022;54(7):1874-80.
31. Duizendstra AA, van der Grift MV, Boor PP, Noordam L, de Knecht RJ, Peppelenbosch MP, Betjes MGH, Litjens NHR, Kwekkeboom J. Current Tolerance-Associated Peripheral Blood Gene Expression Profiles After Liver Transplantation Are Influenced by Immunosuppressive Drugs and Prior Cytomegalovirus Infection. *Front Immunol*. 2021;12:738837.

32. Eikenboom EL, van der Werf-'t Lam AS, Rodriguez-Gironde M, Van Asperen CJ, Dinjens WNM, Hofstra RMW, Van Leerdam ME, Morreau H, Spaander MCW, Wagner A, Nielsen M. Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas. *Clin Gastroenterol Hepatol.* 2022;20(3):e496-e507.
33. Faria AVS, Yu B, Mommersteeg M, de Souza-Oliveira PF, Andrade SS, Spaander MCW, de Maat MPM, Peppelenbosch MP, Ferreira-Halder CV, Fuhler GM. Platelet-dependent signaling and Low Molecular Weight Protein Tyrosine Phosphatase expression promote aggressive phenotypic changes in gastrointestinal cancer cells. *Biochim Biophys Acta Mol Basis Dis.* 2022;1868(1):166280.
34. Flander L, Dekker E, Andersen B, Larsen MB, Steele RJ, Malila N, Sarkeala T, van der Vlugt M, de Klerk C, Knottnerus B, Bertels L, Woudstra A, Spaander MCW, Fransen M, Heinavaara S, Dillon M, Ait Ouakrim D, Jenkins M. What can We Learn From High-Performing Screening Programs to Increase Bowel Cancer Screening Participation in Australia? *Cancer Control.* 2022;29:10732748221121383.
35. Frederiks CN, van Munster SN, Nieuwenhuis EA, Alvarez Herrero L, Alkhalaf A, Schenk BE, Schoon EJ, Curvers WL, Koch AD, de Jonge PF, Tang T, Nagengast WB, Westerhof J, Houben M, Bergman J, Pouw RE, Weusten B, Dutch Barrett Expert C. Clinical Relevance of Random Biopsies From the Esophagogastric Junction After Complete Eradication of Barrett's Esophagus is Low. *Clin Gastroenterol Hepatol.* 2022.
36. Furumaya A, Haring MPD, van Rosmalen BV, Klompenhouwer AJ, Besselink MG, de Man RA, JNM IJ, Thomeer MGJ, Kramer M, Coolen MME, Tushuizen ME, Schaapherder AF, de Haas RJ, Duiker EW, Kazemier G, van Delden OM, Verheij J, Takkenberg RB, Cuperus FJC, De Meijer VE, Erdmann JI, Dutch Benign Liver Tumor G. Study protocol for a multicentre nationwide prospective cohort study to investigate the natural course and clinical outcome in benign liver tumours and cysts in the Netherlands: the BELIVER study. *BMJ Open.* 2022;12(9):e055104.
37. van Gaalen MAC, van Pieterse M, van den Brink G, de Ridder L, Rizopoulos D, van der Woude CJ, Escher JC. Rotterdam Transition Test: A Valid Tool for Monitoring Disease Knowledge in Adolescents With Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr.* 2022 Jan 1;74(1):60-67.
38. Gehlen J, Giel AS, Kollges R, Haas SL, Zhang R, Trcka J, Sungur AO, Renziehausen F, Bornholdt D, Jung D, Hoyer PD, Nordenskjold A, Tibboel D, Vlot J, Spaander MCW, Smigiel R, Patkowski D, Roeleveld N, van Rooij IA, de Blaauw I, Holscher A, Pauly M, Leutner A, Fuchs J, Niethammer J, Melissari MT, Jenetzky E, Zwink N, Thiele H, Hilger AC, Hess T, Trautmann J, Marks M, Baumgarten M, Blass G, Landen M, Fundin B, Bulik CM, Pennimpede T, Ludwig M, Ludwig KU, Mangold E, Heilmann-Heimbach S, Moebus S, Herrmann BG, Alsabeah K, Burgos CM, Lilja HE, Azodi S, Stenstrom P, Arnbjornsson E, Frybova B, Lebensztejn DM, Debek W, Kolodziejczyk E, Kozera K, Kierkus J, Kalicinski P, Stefanowicz M, Socha-Banasiak A, Kolejwa M, Piaseczna-Piotrowska A, Czkwianianc E, Nothen MM, Grote P, Rygl M, Reinshagen K, Szychalski N, Ludwikowski B, Hubertus J, Heydweiller A, Ure B, Muensterer OJ, Aubert O, Gosemann JH, Lacher M, Degenhardt P, Boemers TM, Mokrowiecka A, Malecka-Panas E, Wöhr M, Knapp M, Seitz G, de Klein A, Oracz G, Brosens E, Reutter H, Schumacher J. First genome-wide association study of esophageal atresia identifies three genetic risk loci at CTNNA3, FOXF1/FOXC2/FOXL1, and HNF1B. *HGG Adv.* 2022;3(2):100093.

39. Gehring AJ, Mendez P, Richter K, Ertl H, Donaldson EF, Mishra P, Maini M, Boonstra A, Lauer G, de Creus A, Whitaker K, Martinez SF, Weber J, Gainor E, Miller V. Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection. *J Hepatol.* 2022;77(2):525-38.
40. Gines P, Castera L, Lammert F, Graupera I, Serra-Burriel M, Allen AM, Wong VW, Hartmann P, Thiele M, Caballeria L, de Knegt RJ, Grgurevic I, Augustin S, Tsochatzis EA, Schattenberg JM, Guha IN, Martini A, Morillas RM, Garcia-Retortillo M, de Koning HJ, Fabrellas N, Pich J, Ma AT, Diaz MA, Roulot D, Newsome PN, Manns M, Kamath PS, Krag A, LiverScreen Consortium I. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. *Hepatology.* 2022;75(1):219-28.
41. Goetgebuer RL, Masclee GMC, van der Eijk AA, van der Woude CJ, de Man RA, de Vries AC. Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report. *Clin Res Hepatol Gastroenterol.* 2022;46(7):101948.
42. Goetgebuer RL, van der Woude CJ, Bakker L, van der Eijk AA, de Ridder L, de Vries AC. The diagnosis and management of CMV colitis in IBD patients shows high practice variation: a national survey among gastroenterologists. *Scand J Gastroenterol.* 2022 Nov;57(11):1321-1326.
43. Graupera I, Thiele M, Ma AT, Serra-Burriel M, Pich J, Fabrellas N, Caballeria L, de Knegt RJ, Grgurevic I, Reichert M, Roulot D, Schattenberg JM, Pericas JM, Angeli P, Tsochatzis EA, Guha IN, Garcia-Retortillo M, Morillas RM, Hernandez R, Hoyo J, Fuentes M, Madir A, Juanola A, Soria A, Juan M, Carol M, Diaz A, Detlefsen S, Toran P, Fournier C, Llorca A, Newsome PN, Manns M, de Koning HJ, Serra-Burriel F, Cucchietti F, Arslanow A, Korenjak M, van Kleef L, Falco JL, Kamath PS, Karlsen TH, Castera L, Lammert F, Krag A, Gines P, LiverScreen Consortium i. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries. *BMC Public Health.* 2022;22(1):1385.
44. Gorris M, van Huijgevoort NCM, Farina A, Brosens LAA, van Santvoort HC, Groot Koerkamp B, Bruno MJ, Besselink MG, van Hooft JE, Dutch Pancreatic Cancer G. Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts: Nationwide Registry-Based Study. *Cancers (Basel).* 2022;14(17).
45. Gotink AW, Peters Y, Bruno MJ, Siersema PD, Koch AD. Nonthermal resection device for ablation of Barrett's esophagus: a feasibility and safety study. *Endoscopy.* 2022 Jun;54(6):545-552.
46. Gotink AW, van de Ven SEM, Ten Kate FJC, Nieboer D, Suzuki L, Weusten BLAM, Brosens LAA, van Hillegersberg R, Alvarez Herrero L, Seldenrijk CA, Alkhalaf A, Moll FCP, Schoon EJ, van Lijnschoten I, Tang TJ, van der Valk H, Nagengast WB, Kats-Ugurlu G, Plukker JTM, Houben MHMG, van der Laan JS, Pouw RE, Bergman JJGHM, Meijer SL, van Berge Henegouwen MI, Wijnhoven BPL, de Jonge PJJ, Doukas M, Bruno MJ, Biermann K, Koch AD. Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. *Endoscopy.* 2022 Feb;54(2):109-117.
47. Gritter M, Ramakers C, de Man RA, Hoorn EJ, Rotmans JI. [Pseudohyperkalemia: clinical chemistry for the clinician] Pseudohyperkaliemie: klinische chemie voor klinici. *Ned Tijdschr Geneeskd.* 2022;166.
48. Guo X, Spaander MCW, Fuhler GM. Enterochromaffin-like Cell Hyperplasia as Identification Marker of Autoimmune Gastritis in Patients With Helicobacter pylori Infection in the Context of Gastric Premalignant Lesions. *Arch Pathol Lab Med.* 2022;146(10):1181-2.

49. Hallensleben ND, Timmerhuis HC, Hollemans RA, Pocornie S, van Grinsven J, van Brunschot S, Bakker OJ, van der Sluijs R, Schwartz MP, van Duijvendijk P, Römken T, Stommel MWJ, Verdonk RC, Besselink MG, Bouwense SAW, Bollen TL, van Santvoort HC, Bruno MJ; Dutch Pancreatitis Study Group. Optimal timing of cholecystectomy after necrotising biliary pancreatitis. *Gut*. 2022 May;71(5):974-982.
50. Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld MJ, Chan HLY, Fornis X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA, Group R-BS. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). *Gastroenterology*. 2022;162(3):757-71 e4.
51. Hirode G, Janssen HLA. Reply. *Gastroenterology*. 2022;163(3):779-80.
52. Hoefnagel SJM, Koemans WJ, Khan HN, Koster J, Meijer SL, van Dieren JM, Kodach LL, van Sandick JW, Calpe S, Del Sancho-Serra CM, Correia ACP, Van Berge Henegouwen MI, Gisbertz SS, Hulshof M, Mattioli S, Spaander MCW, Krishnadath KK. Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies. *Cancers (Basel)*. 2022;14(18).
53. Hoogeveen RC, Dijkstra S, Bartsch LM, Drescher HK, Aneja J, Robidoux MP, Cheney JA, Timm J, Gehring A, de Sousa PSF, Ximenez L, Peliganga LB, Pitts A, Evans FB, Boonstra A, Kim AY, Lewis-Ximenez LL, Lauer GM. Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen(+) infection. *J Hepatol*. 2022;77(5):1276-86.
54. Isfordink CJ, van Dijk M, Brakenhoff SM, Kracht PAM, Arends JE, de Knecht RJ, van der Valk M, Drenth JPH, Group CS. Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination. *Eur J Intern Med*. 2022;101:93-7.
55. Johnson Valiente A, Liem KS, Schwarz KB, Rosenthal P, Murray KF, Mogul D, Teckman J, Rodriguez-Baez N, Schwarzenberg SJ, Feld JJ, Wong DK, Lewis-Ximenez LL, Lauer G, Hansen BE, Ling SC, Janssen HLA, Gehring AJ. The Inflammatory Cytokine Profile Associated With Liver Damage Is Broader and Stronger in Patients With Chronic Hepatitis B Compared to Patients With Acute Hepatitis B. *J Infect Dis*. 2022;225(3):470-5.
56. Katwaroe WK, Brakenhoff SM, van der Spek DPC, de Knecht RJ, van Kleef LA, de Man RA, van der Meer AJP, Sonneveld MJ, The Icarus Study G. Assessment of Adherence to Clinical Guidelines in Patients with Chronic Hepatitis B. *Viruses*. 2022;14(10).
57. Kamp E, Dinjens WNM, van Velthuysen MF, de Jonge PJF, Bruno MJ, Peppelenbosch MP, de Vries AC. Next-generation sequencing mutation analysis on biliary brush cytology for differentiation of benign and malignant strictures in primary sclerosing cholangitis. *Gastrointest Endosc*. 2022.
58. Kamp EJ, Dinjens WN, Doukas M, van Marion R, Verheij J, Ponsioen CY, Bruno MJ, Groot Koerkamp B, Trivedi PJ, Peppelenbosch MP, de Vries AC. Genetic alterations during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis. *J Pathol*. 2022 Nov;258(3):227-235.
59. Keulen AV, Gaspersz MP, van Vugt JLA, Roos E, Olthof PB, Coelen RJS, Bruno MJ, van Driel L, Voermans RP, van Eijck CHJ, van Hooft JE, van Lienden KP, de Jonge J, Polak WG, Poley JW, Pek CJ, Moelker A, Willemsen F, van

- Gulik TM, Erdmann JI, Hol L, JNM IJ, Buttner S, Koerkamp BG. Success, complication, and mortality rates of initial biliary drainage in patients with unresectable perihilar cholangiocarcinoma. *Surgery*. 2022;172(6):1606-13.
60. Klatte DCF, Wallace MB, Lohr M, Bruno MJ, van Leerdam ME. Hereditary pancreatic cancer. *Best Pract Res Clin Gastroenterol*. 2022;58-59:101783.
61. Kempers EK, van Kwawegen CB, de Meris J, Spaander MCW, Schols SEM, Ypma PF, Heubel-Moenen F, van Vulpen LFD, Coppens M, van der Bom JG, Fijnvandraat K, Meijer K, Eikenboom J, Gouw SC, Leebeek FWG, Kruij M. Colorectal cancer screening in patients with inherited bleeding disorders: high cancer detection rate in hemophilia patients. *J Thromb Haemost*. 2022.
62. Kok G, Verstegen MMA, Houwen RHJ, Nieuwenhuis EES, Metselaar HJ, Polak WG, van der Laan LJW, Spierings E, den Hoed CM, Fuchs SA. Assessment of human leukocyte antigen matching algorithm PIRCHE-II on liver transplantation outcomes. *Liver Transpl*. 2022;28(8):1356-66.
63. Kwakman JA, Rauwers AW, Buijs JG, de Groot W, Vos MC, Bruno MJ. No relation between adenosine triphosphate after manual cleaning and presence of microorganisms on endoscopes after automated high-level disinfection. *Endosc Int Open*. 2022;10(9):E1275-E81.
64. Kwakman JA, Vos MC, Bruno MJ. Higher yield in duodenoscope cultures collected with addition of neutralizing agent. *J Hosp Infect*. 2022;132:28-35.
65. Kwakman JA, Bexkens ML, Bruno MJ, Vos MC. Persistent contamination of a duodenoscope working channel in a non-clinical simulated ERCP setting. *Endoscopy*. 2022 Nov;54(11):1085-1090. doi: 10.1055/a-1814-4379.
66. Kwakman JA, Erler NS, Vos MC, Bruno MJ. Risk evaluation of duodenoscope-associated infections in the Netherlands calls for a heightened awareness of device-related infections: a systematic review. *Endoscopy*. 2022 Feb;54(2):148-155.
67. Küttner-Magalhães R, Dinis-Ribeiro M, Marcos-Pinto R, Rolanda C, Koch AD. Endoscopic Submucosal Dissection Skills Transfer to Clinical Practice after Hands-On Workshops: An International Survey. *Dig Dis*. 2022;40(5):665-674.
68. Küttner-Magalhães R, Dinis-Ribeiro M, Bruno MJ, Marcos-Pinto R, Rolanda C, Koch AD. A Steep Early Learning Curve for Endoscopic Submucosal Dissection in the Live Porcine Model. *Dig Dis*. 2022;40(6):816-825. doi: 10.1159/000521429.
69. Lam SY, Mommersteeg MC, Yu B, Broer L, Spaander MCW, Frost F, Weiss S, Volzke H, Lerch MM, Schottker B, Zhang Y, Stocker H, Brenner H, Levy D, Hwang SJ, Wood AC, Rich SS, Rotter JI, Taylor KD, Tracy RP, Kabagambe EK, Leja M, Klovins J, Peculis R, Rudzite D, Nikitina-Zake L, Skenders G, Rovite V, Uitterlinden A, Kuipers EJ, Fuhler GM, Homuth G, Peppelenbosch MP. Toll-Like Receptor 1 Locus Re-examined in a Genome-Wide Association Study Update on Anti-Helicobacter pylori IgG Titers. *Gastroenterology*. 2022;162(6):1705-15.
70. Levink IJM, Klatte DCF, Hanna-Sawires RG, Vreeker GCM, Ibrahim IS, van der Burgt YEM, Overbeek KA, Koopmann BDM, Cahen DL, Fuhler GM, Wuhrer M, Bonsing BA, Tollenaar RAEM, Vleggaar FP, Vasen HFA, van Leerdam ME, Bruno MJ, Mesker WE. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals. *Pancreatology*. 2022 May;22(4):497-506.

71. Levink IJM, Visser IJ, Koopmann BDM, van Driel LMJW, Poley JW, Cahen DL, Bruno MJ, Fuhler GM. Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer. *Gastrointest Endosc.* 2022 Nov;96(5):801-813.e2.
72. Levink IJM, Brosens LAA, Rensen SS, Aberle MR, Olde Damink SSW, Cahen DL, Buschow SI, Fuhler GM, Peppelenbosch MP, Bruno MJ. Neoantigen Quantity and Quality in Relation to Pancreatic Cancer Survival. *Front Med (Lausanne).* 2022 Feb 9;8:751110.
73. Li J, Ayada I, Wang Y, den Hoed CM, Kamar N, Peppelenbosch MP, de Vries AC, Li P, Pan Q. Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis. *Transplantation.* 2022;106(10):2068-75.
74. Li P, Li Y, Wang Y, Liu J, Lavrijsen M, Li Y, Zhang R, Verstegen MMA, Wang Y, Li TC, Ma Z, Kainov DE, Bruno MJ, de Man RA, van der Laan LJW, Peppelenbosch MP, Pan Q. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. *Sci Adv.* 2022;8(3):eabj5908.
75. Li Y, Li P, de Man RA, Peppelenbosch MP, Pan Q. Probing the direct effects of antiretroviral drugs on hepatitis E virus replication in cell culture models. *Liver Int.* 2022;42(3):716-7.
76. Li Y, Li P, He Q, Zhang R, Li Y, Kamar N, Peppelenbosch MP, de Man RA, Wang L, Pan Q. Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling. *Antiviral Res.* 2022;197:105228.
77. Li Y, Yu P, Kessler AL, Shu J, Liu X, Liang Z, Liu J, Li Y, Li P, Wang L, Wang Y, Ma Z, Liu A, Wang L, Bruno MJ, de Man RA, Peppelenbosch MP, Buschow SI, Wang L, Wang Y, Pan Q. Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable. *Hepatology.* 2022;75(1):196-212.
78. Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, Pan Q. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. *Cell Res.* 2022 Mar;32(3):322-324.
79. Libanio D, Rodrigues JR, Bento MJ, Ebigbo A, Messman H, Verhoeven RHA, Van Damme N, Bisschops R, Spaander MCW, Dinis-Ribeiro M. Gastric cancer incidence and mortality trends 2007-2016 in three European countries. *Endoscopy.* 2022;54(7):644-52.
80. Liem KS, Chi H, Fung S, Wong DK, Yim C, Noureldin S, Chen J, de Man RA, Sarowar A, Feld JJ, Hansen BE, Hou J, Peng J, Janssen HLA. Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. *J Viral Hepat.* 2022;29(11):986-93.
81. Lieshout R, Kamp E, Verstegen MMA, Doukas M, Dinjens WNM, Kotev K, JNM IJ, Bruno MJ, Peppelenbosch MP, van der Laan LJW, de Vries AC. Cholangiocarcinoma cell proliferation is enhanced in primary sclerosing cholangitis: A role for IL-17A. *Int J Cancer.* 2022.
82. Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Kneegt RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. *Clin Gastroenterol Hepatol.* 2022;20(3):e573-e82.
83. Liu WY, Zhang X, Li G, Tang LJ, Zhu PW, Rios RS, Zheng KI, Ma HL, Wang XD, Pan Q, de Kneegt RJ, Valenti L, Ghanbari M, Zheng MH. Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. *Clin Mol Hepatol.* 2022;28(2):183-95.

84. Ma Z, de Man RA, Kamar N, Pan Q. Chronic hepatitis E: Advancing research and patient care. *J Hepatol.* 2022;77(4):1109-23.
85. Mahadevan U, Naureckas S, Tikhonov I, Wang Y, Lin CB, Geldhof A, van der Woude CJ. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database. *Aliment Pharmacol Ther.* 2022 Aug;56(3):477-490.
86. Metz FM, Blauw JTM, Brusse-Keizer M, Kolkman JJ, Bruno MJ, Geelkerken RH, Dutch Mesenteric Ischaemia Study G. Systematic Review of the Efficacy of Treatment for Median Arcuate Ligament Syndrome. *Eur J Vasc Endovasc Surg.* 2022;64(6):720-32.
87. Moen S, Vuik FER, Kuipers EJ, Spaander MCW. Artificial Intelligence in Colon Capsule Endoscopy-A Systematic Review. *Diagnostics (Basel).* 2022;12(8).
88. Moen S, Vuik FER, Voortman T, Kuipers EJ, Spaander MCW. Predictors of Gastrointestinal Transit Times in Colon Capsule Endoscopy. *Clin Transl Gastroenterol.* 2022;13(6):e00498.
89. Mommersteeg MC, Simovic I, Yu B, van Nieuwenburg SAV, Bruno IMJ, Doukas M, Kuipers EJ, Spaander MCW, Peppelenbosch MP, Castano-Rodriguez N, Fuhler GM. Autophagy mediates ER stress and inflammation in *Helicobacter pylori*-related gastric cancer. *Gut Microbes.* 2022;14(1):2015238.
90. Mommersteeg MC, Yu BT, van den Bosch TPP, von der Thusen JH, Kuipers EJ, Doukas M, Spaander MCW, Peppelenbosch MP, Fuhler GM. Constitutive programmed death ligand 1 expression protects gastric G-cells from *Helicobacter pylori*-induced inflammation. *Helicobacter.* 2022;27(5):e12917.
91. Montanari NR, Conceicao-Neto N, Van Den Wyngaert I, Van Oord GW, Groothuismink ZMA, Van Tilburg S, de Man RA, Aerssens J, Boonstra A. Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients. *J Infect Dis.* 2022;225(8):1471-6.
92. Montanari NR, Ramirez R, Aggarwal A, van Buuren N, Doukas M, Moon C, Turner S, Diehl L, Li L, Debes JD, Feierbach B, Boonstra A. Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection. *J Hepatol.* 2022;77(2):332-43.
93. Mulder MB, Doga B, Borgsteede SD, van den Burg AM, Metselaar HJ, den Hoed CM, Hunfeld NGM. Evaluation of medication-related problems in liver transplant recipients with and without an outpatient medication consultation by a clinical pharmacist: a cohort study. *Int J Clin Pharm.* 2022;44(5):1114-22.
94. Mulder MB, van der Eijk AA, GeurtsvanKessel CH, Erler NS, de Winter BCM, Polak WG, Metselaar HJ, den Hoed CM. High antibody response in relation to immunosuppressive blood levels in liver transplant recipients after SARS-CoV-2 vaccination: an observational, cohort study. *Gut.* 2022;71(12):2605-8.
95. Murillo Perez CF, Fisher H, Hiu S, Kareithi D, Adekunle F, Mayne T, Malecha E, Ness E, van der Meer AJ, Lammers WJ, Trivedi PJ, Battezzati PM, Nevens F, Kowdley KV, Bruns T, Cazzagon N, Floreani A, Mason AL, Pares A, Londono MC, Invernizzi P, Carbone M, Lleo A, Mayo MJ, Dalekos GN, Gatselis NK, Thorburn D, Verhelst X, Gulamhusein A, Janssen HLA, Smith R, Flack S, Mulcahy V, Trauner M, Bowlus CL, Lindor KD, Corpechot C, Jones D, Mellis G, Hirschfield GM, Wason J, Hansen BE, Group GPS, the members of the UKPBCC. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. *Gastroenterology.* 2022;163(6):1630-42 e3.

96. Nass KJ, van der Schaar PJ, van der Vlugt M, Ledebouwer M, van Esch AAJ, van der Beek S, Lacle MM, van Leerdam ME, Ouwendijk RJT, Spaander MCW, Wouters M, Fockens P, Dekker E. Continuous monitoring of colonoscopy performance in the Netherlands: first results of a nationwide registry. *Endoscopy*. 2022;54(5):488-95.
97. Nesteruk K, Levink IJM, de Vries E, Visser IJ, Peppelenbosch MP, Cahen DL, Fuhler GM, Bruno MJ. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma. *Pancreatology*. 2022 Jun;22(5):626-635.
98. Nesteruk K, Levink IJM, Dits NFJ, Cahen DL, Peppelenbosch MP, Bruno MJ, Fuhler GM. Size and Concentration of Extracellular Vesicles in Pancreatic Juice From Patients With Pancreatic Ductal Adenocarcinoma. *Clin Transl Gastroenterol*. 2022 Feb 18;13(3):e00465.
99. Nieuwenburg SAV, Mommersteeg MC, Wolters LMM, van Vuuren AJ, Erler N, Peppelenbosch MP, Fuhler GM, Bruno MJ, Kuipers EJ, Spaander MCW. Accuracy of H. pylori fecal antigen test using fecal immunochemical test (FIT). *Gastric Cancer*. 2022;25(2):375-81.
100. Nieuwenhuis EA, van Munster SN, Meijer SL, Brosens LAA, Jansen M, Weusten BLAM, Alvarez Herrero L, Alkhalaf A, Schenk E, Schoon EJ, Curvers WL, Koch AD, van de Ven SEM, Verheij EPD, Nagengast WB, Westerhof J, Houben MHMG, Tang T, Bergman JJGHM, Pouw RE; Dutch Barrett Expert Centers. Analysis of metastases rates during follow-up after endoscopic resection of early "high-risk" esophageal adenocarcinoma. *Gastrointest Endosc*. 2022 Aug;96(2):237-247.e3.
101. Nieuwenhuis EA, van Munster SN, Curvers WL, Weusten B, Alvarez Herrero L, Bogte A, Alkhalaf A, Schenk BE, Koch AD, Spaander MCW, Tang TJ, Nagengast WB, Westerhof J, Houben M, Bergman J, Schoon EJ, Pouw RE, Dutch Barrett Expert C. Correction: Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitals. *Endoscopy*. 2022;54(10):C15.
102. Nieuwenhuis EA, van Munster SN, Curvers WL, Weusten B, Alvarez Herrero L, Bogte A, Alkhalaf A, Schenk BE, Koch AD, Spaander MCW, Tang TJ, Nagengast WB, Westerhof J, Houben M, Bergman J, Schoon EJ, Pouw RE, Dutch Barrett Expert C. Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitals. *Endoscopy*. 2022;54(10):936-44.
103. Noordam L, de Beijer MTA, Mancham S, Vogler I, Boor PPC, de Ruiten V, Luijten R, JNM II, Sahin U, Bruno MJ, Sprengers D, Buschow SI, Kwekkeboom J. Systemic T-cell and humoral responses against cancer testis antigens in hepatocellular carcinoma patients. *Oncoimmunology*. 2022;11(1):2131096.
104. Onnekink AM, Boxhoorn L, Timmerhuis HC, Bac ST, Besselink MG, Boermeester MA, Bollen TL, Bosscha K, Bouwense SAW, Bruno MJ, van Brunschot S, Cappendijk VC, Consten ECJ, Dejong CH, Dijkgraaf MGW, van Eijck CHJ, Erkelens WG, van Goor H, van Grinsven J, Haveman JW, van Hooft JE, Jansen JM, van Lienden KP, Meijssen MAC, Nieuwenhuijs VB, Poley JW, Quispel R, de Ridder RJ, Römkens TEH, van Santvoort HC, Scheepers JJ, Schwartz MP, Seerden T, Spanier MBW, Straathof JWA, Timmer R, Venneman NG, Verdonk RC, Vleggaar FP, van Wanrooij RL, Witteman BJM, Fockens P, Voermans RP; Dutch Pancreatitis Study Group. Endoscopic Versus Surgical Step-Up Approach for Infected Necrotizing Pancreatitis (ExTENSION): Long-term Follow-up of a Randomized Trial. *Gastroenterology*. 2022 Sep;163(3):712-722.e14.
105. Overbeek KA, Goggins MG, Dbouk M, Levink IJM, Koopmann BDM, Chuidian M, Konings ICAW, Paiella S, Earl J, Fockens P, Gress TM, Ausems MGEM, Poley JW, Thosani NC, Half E, Lachter J, Stoffel EM,

- Kwon RS, Stoita A, Kastrinos F, Lucas AL, Syngal S, Brand RE, Chak A, Carrato A, Vleggaar FP, Bartsch DK, van Hooft JE, Cahen DL, Canto MI, Bruno MJ; International Cancer of the Pancreas Screening Consortium. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. *Gastroenterology*. 2022 Mar;162(3):772-785.e4.
106. Overbeek KA, Levink IJM, Koopmann BDM, Harinck F, Konings ICAW, Ausems MGEM, Wagner A, Fockens P, van Eijck CH, Groot Koerkamp B, Busch ORC, Besselink MG, Bastiaansen BAJ, van Driel LMJW, Erler NS, Vleggaar FP, Poley JW, Cahen DL, van Hooft JE, Bruno MJ; Dutch Familial Pancreatic Cancer Surveillance Study Group. Long-term yield of pancreatic cancer surveillance in high-risk individuals. *Gut*. 2022 Jun;71(6):1152-1160.
107. Overbeek KA, van Leeuwen N, Tacelli M, Anwar MS, Yousaf MN, Chhoda A, Arcidiacono PG, Gonda TA, Wallace MB, Capurso G, Farrell JJ, Cahen DL, Bruno MJ. International external validation of a stratification tool to identify branch- duct intraductal papillary mucinous neoplasms at lowest risk of progression. *United European Gastroenterol J*. 2022 Mar;10(2):169-178.
108. Paulides E, Cornelissen D, de Vries AC, van der Woude CJ. Inflammatory bowel disease negatively impacts household and family life. *Frontline Gastroenterol*. 2022;13(5):402-8.
109. Paulides E, Pasma A, Erler NS, van Eijk RLA, de Vries AC, van der Woude CJ. Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease. *Dig Dis Sci*. 2022 Jul;67(7):2849-2856.
110. Paulides E, Lie MRKL, van der Woude CJ. Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study. *BMJ Open*. 2022 Apr 8;12(4):e058358.
111. Pauwels RWM, van der Woude CJ, Nieboer D, Steyerberg EW, Casanova MJ, Gisbert JP, Kennedy NA, Lees CW, Louis E, Molnár T, Szántó K, Leo E, Bots S, Downey R, Lukas M, Lin WC, Amiot A, Lu C, Roblin X, Farkas K, Seidelin JB, Duijvestein M, D'Haens GR, de Vries AC; CEASE Study Group. Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. *Clin Gastroenterol Hepatol*. 2022 Aug;20(8):1671-1686.e16.
112. Portilla-Fernandez E, Klarin D, Hwang SJ, Biggs ML, Bis JC, Weiss S, Rospleszcz S, Natarajan P, Hoffmann U, Rogers IS, Truong QA, Volker U, Dorr M, Bulow R, Criqui MH, Allison M, Ganesh SK, Yao J, Waldenberger M, Bamberg F, Rice KM, Essers J, Kapteijn DMC, van der Laan SW, de Kneegt RJ, Ghanbari M, Felix JF, Ikram MA, Kavousi M, Uitterlinden AG, Roks AJM, Danser AHJ, Tsao PS, Damrauer SM, Guo X, Rotter JI, Psaty BM, Kathiresan S, Volzke H, Peters A, Johnson C, Strauch K, Meitinger T, O'Donnell CJ, Dehghan A, Program VAMV. Genetic and clinical determinants of abdominal aortic diameter: genome-wide association studies, exome array data and Mendelian randomization study. *Hum Mol Genet*. 2022;31(20):3566-79.
113. Rauwers AW, Voor In 't Holt AF, Buijs JG, Groot W, Erler NS, Vos MC, Bruno MJ. Assessment of postmanual cleaning adenosine triphosphate tests to prevent the use of contaminated duodenoscopes and linear echoendoscopes: the DETECT study. *Gastrointest Endosc*. 2022 Aug;96(2):282-290.e5.
114. Refardt J, den Hoed CM, Langendonk J, Zandee WT, Charehbili A, Feelders RA, de Herder WW, Brabander T, Hofland J. Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases. *Endocr Relat Cancer*. 2022;29(5):241-50.

115. Reijm AN, Zellenrath PA, van der Bogt RD, van Driel L, Siersema PD, Bruno MJ, Spaander MCW. Self-expandable duodenal metal stent placement for the palliation of gastric outlet obstruction over the past 20 years. *Endoscopy*. 2022;54(12):1139-46.
116. Rico Montanari N, Ramirez R, Van Buuren N, van den Bosch TPP, Doukas M, Debes JD, Feierbach B, Boonstra A. Transcriptomic Analysis of Livers of Inactive Carriers of Hepatitis B Virus With Distinct Expression of Hepatitis B Surface Antigen. *J Infect Dis*. 2022;225(6):1081-90.
117. de Rijk FEM, van Veldhuisen CL, Besselink MG, van Hooft JE, van Santvoort HC, van Geenen EJM, Hegyi P, Löhr JM, Dominguez-Munoz JE, de Jonge PJF, Bruno MJ, Verdonk RC; Dutch Pancreatitis Study Group. Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: An international expert survey and case vignette study. *Pancreatology*. 2022 May;22(4):457-465.
118. Roumans CAM, van der Bogt RD, Nieboer D, Steyerberg EW, Rizopoulos D, Lansdorp-Vogelaar I, Biermann K, Bruno MJ, Spaander MCW. Clinical consequences of nonadherence to Barrett's esophagus surveillance recommendations: a Multicenter prospective cohort study. *Dis Esophagus*. 2022.
119. Roumans CAM, Spaander MCW, Lansdorp-Vogelaar I, Biermann K, Bruno MJ, Steyerberg EW, Rizopoulos D; ProBar study group. A personalized and dynamic risk estimation model: The new paradigm in Barrett's esophagus surveillance. *PLoS One*. 2022 Apr 27;17(4):e0267503.
120. Roumans CAM, Zellenrath PA, Steyerberg EW, Lansdorp-Vogelaar I, Doukas M, Biermann K, Alderliesten J, van Ingen G, Nagengast WB, Karrenbeld A, Ter Borg F, Hage M, Ter Borg PCJ, den Bakker MA, Alkhalaf A, Moll FCP, Brouwer-Hol L, van Baarlen J, Quispel R, van Tilburg A, Burger JPW, van Tilburg AJP, Ooms A, Tang TJ, Romberg-Camps MJL, Goudkade D, Bruno MJ, Rizopoulos D, Spaander MCW. Sex Differences in Neoplastic Progression in Barrett's Esophagus: A Multicenter Prospective Cohort Study. *Cancers (Basel)*. 2022;14(13).
121. Schutz HM, Quispel R, Veldt BJ, Smedts FMM, Anten MGF, Hoogduin KJ, Honkoop P, van Nederveen FH, Hol L, Kliffen M, Fitzpatrick CE, Erler NS, Bruno MJ, van Driel LMJW; QUEST. Cumulative sum learning curves guiding multicenter multidisciplinary quality improvement of EUS-guided tissue acquisition of solid pancreatic lesions. *Endosc Int Open*. 2022 Apr 14;10(4):E549-E557.
122. Sleutjes JAM, Roeters van Lennep JE, van der Woude CJ, de Vries AC. Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. *Inflamm Bowel Dis*. 2022 May 19.
123. Sleutjes JAM, Roeters van Lennep JE, Verploegh PJP, van Doorn MBA, Vis M, Kavousi M, van der Woude CJ, de Vries AC. Prevalence of ideal cardiovascular health and its correlates in patients with inflammatory bowel disease, psoriasis and spondyloarthritis. *Eur J Prev Cardiol*. 2022 Oct 18;29(13):e314-e318.
124. Sonneveld MJ, Chiu SM, Chen CH, Maasoumy B, group Cs. Reply to: "Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels". *J Hepatol*. 2022;77(4):1224-6.
125. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bommel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Honer Zu Siederdisen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B, group Cs. Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels. *J Hepatol*. 2022;76(5):1042-50.

126. Sonneveld MJ, Hansen BE, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, de Kneegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA, Group S-BS. Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. *J Infect Dis.* 2022;225(11):1967-73.
127. Sonneveld MJ, Hardeman S, Kuipers EJ, de Graaf W, Spaander MCW, van der Meer AJ. Effect of the COVID-19 pandemic on procedure volumes in gastroenterology in the Netherlands. *Lancet Gastroenterol Hepatol.* 2022;7(7):595-8.
128. Sonneveld MJ, Maasoumy B. Reply. *Clin Gastroenterol Hepatol.* 2022;20(4):e910-e1.
129. Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bommel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Honer Zu Siederdisen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B, Group CS. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). *Clin Gastroenterol Hepatol.* 2022;20(4):e784-e93.
130. Sonneveld MJ, Veldhuijzen IK, van de Laar TJW, Op de Coul ELM, van der Meer AJ. Decrease in viral hepatitis diagnoses during the COVID-19 pandemic in the Netherlands. *J Hepatol.* 2022;77(3):896-7.
131. Sperna Weiland CJ, Busch CBE, Bhalla A, Bruno MJ, Fockens P, van Hooft JE, Poen AC, Timmerhuis HC, Umans DS, Venneman NG, Verdonk RC, Drenth JPH, de Wijkerslooth TR, van Geenen EJM; Dutch Pancreatitis Study Group. Performance of diagnostic tools for acute cholangitis in patients with suspected biliary obstruction. *J Hepatobiliary Pancreat Sci.* 2022 Apr;29(4):479-486.
132. Sperna Weiland CJ, Verschoor EC, Poen AC, Smeets X, Venneman NG, Bhalla A, Witteman BJM, Timmerhuis HC, Umans DS, van Hooft JE, Bruno MJ, Fockens P, Verdonk RC, Drenth JPH, van Geenen EJM, Dutch Pancreatitis Study G. Suspected common bile duct stones: reduction of unnecessary ERCP by pre-procedural imaging and timing of ERCP. *Surg Endosc.* 2022.
133. Sperna Weiland CJ, Smeets XJNM, Verdonk RC, Poen AC, Bhalla A, Venneman NG, Kievit W, Timmerhuis HC, Umans DS, van Hooft JE, Besselink MG, van Santvoort HC, Fockens P, Bruno MJ, Drenth JPH, van Geenen EJM; Dutch Pancreatitis Study Group. Optimal timing of rectal diclofenac in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. *Endosc Int Open.* 2022 Mar 14;10(3):E246-E253.
134. Stassen PMC, de Jonge PJF, Bruno MJ, Koch AD, Trindade AJ, Benias PC, Sejpal DV, Siddiqui UD, Chapman CG, Villa E, Tharian B, Inamdar S, Hwang JH, Barakat MT, Andalib I, Gaidhane M, Sarkar A, Shahid H, Tyberg A, Binmoeller K, Watson RR, Nett A, Schlag C, Abdelhafez M, Friedrich-Rust M, Schlachterman A, Chiang AL, Loren D, Kowalski T, Kahaleh M. Safety and efficacy of a novel resection system for direct endoscopic necrosectomy of walled-off pancreas necrosis: a prospective, international, multicenter trial. *Gastrointest Endosc.* 2022 Mar;95(3):471-479.
135. Ten Bokkel Huinink S, de Jong DC, Nieboer D, Thomassen D, Steyerberg EW, Dijkgraaf MGW, Bodelier AGL, West RL, Romkens TEH, Hoentjen F, Mallant RC, van Tuyl BAC, Mares WGN, Wolfhagen FHJ, Dijkstra G, Reijnders JGP, de Boer NK, Tan A, van Boeckel PGA, Tack GJ, van Asseldonk DP, D'Haens G, van der Woude CJ, Duijvestein M, de Vries AC. Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease. *Eur J Gastroenterol Hepatol.* 2022;34(10):983-92.

136. Ten Kate CA, de Klein A, de Graaf BM, Doukas M, Koivusalo A, Pakarinen MP, van der Helm R, Brands T, H IJ, van Bever Y, Wijnen RMH, Spaander MCW, Brosens E. Intrinsic Cellular Susceptibility to Barrett's Esophagus in Adults Born with Esophageal Atresia. *Cancers (Basel)*. 2022;14(3).
137. Ten Kate CA, Teunissen NM, van Rosmalen J, Kamphuis LS, van Wijk MP, Joosten M, van Tuyl van Serooskerken ES, Wijnen R, H IJ, Rietman AB, Spaander MCW. Development and validation of a condition-specific quality of life instrument for adults with esophageal atresia: the SQEA questionnaire. *Dis Esophagus*. 2022.
138. Ten Kate CA, van Hal ARL, Erler NS, Doukas M, Nikkessen S, Vlot J, H IJ, Wijnhoven BPL, Wijnen RMH, Spaander MCW. Recommendations for endoscopic surveillance after esophageal atresia repair in adults. *Dis Esophagus*. 2022;35(7).
139. Terlouw LG, van Dijk LJD, van Noord D, Voogd T, Bakker BJ, Nikkessen S, Bruno MJ, Moelker A. MRI-based pre- and postprandial flow in the mesenteric vasculature of patients with suspected chronic mesenteric ischemia. *Eur J Radiol*. 2022 Jun;151:110316.
140. Theel W, Boxma-de Klerk BM, Dirksmeier-Harinck F, van Rossum EFC, Kanhai DA, Apers J, van Dalen BM, de Knecht RJ, Holleboom AG, Tushuizen ME, Grobbee DE, Wiebolt J, Castro Cabezas M. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. *Obes Rev*. 2022;23(8):e13481.
141. Theunissen F, van der Wiel SE, Ter Borg PCJ, Koch AD, Ouwendijk RJT, Slangen RME, Siersema PD, Bruno MJ; Trans.IT foundation study group. Implementation of mandatory ERCP registration in The Netherlands and compliance with European Society of Gastrointestinal Endoscopy performance measures: a multicenter database study. *Endoscopy*. 2022 Mar;54(3):262-267.
142. Timmerhuis HC, van Dijk SM, Hollemans RA, Sperna Weiland CJ, Umans DS, Boxhoorn L, Hallensleben NH, van der Sluijs R, Brouwer L, van Duijvendijk P, Kager L, Kuiken S, Poley JW, de Ridder R, Romkens T, Quispel R, Schwartz MP, Tan A, Venneman NG, Vleggaar FP, van Wanrooij RLJ, Witteman BJ, van Geenen E, Molenaar IQ, Bruno MJ, van Hooft JE, Besselink MG, Voermans RP, Bollen TL, Verdonk RC, van Santvoort HC, Dutch Pancreatitis Study G. Short- and long-term outcomes of a disruption and disconnection of the pancreatic duct in necrotizing pancreatitis: a multicenter cohort study in 896 patients : Disrupted pancreatic duct in acute pancreatitis. *Am J Gastroenterol*. 2022.
143. Timmerhuis HC, van Dijk SM, Hollemans RA, Umans DS, Sperna Weiland CJ, Besselink MG, Bouwense SAW, Bruno MJ, van Duijvendijk P, van Eijck CHJ, Issa Y, Mieog S, Molenaar IQ, Stommel MWJ, Bollen TL, Voermans RP, Verdonk RC, van Santvoort HC; Dutch Pancreatitis Study Group. Perforation and Fistula of the Gastrointestinal Tract in Patients with Necrotizing Pancreatitis: a Nationwide Prospective Cohort. *Ann Surg*. 2022 Jul 22.
144. Toes-Zoutendijk E, Vink G, Nagtegaal ID, Spaander MCW, Dekker E, van Leerdam ME, Siesling S, Lansdorp-Vogelaar I, Elferink MAG, Covid, Cancer NLc. Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. *Eur J Cancer*. 2022;161:38-43.
145. Tokat M, van Tilburg L, Koch AD, Spaander MCW. Artificial Intelligence in Upper Gastrointestinal Endoscopy. *Dig Dis*. 2022;40(4):395-408.
146. van de Ven SEM, Spaander MCW, Pouw RE, Tang TJ, Houben M, Schoon EJ, de Jonge PJF, Bruno MJ, Koch AD. Favorable effect of endoscopic reassessment of clinically staged T2 esophageal adenocarcinoma: a multicenter prospective cohort study. *Endoscopy*. 2022;54(2):163-9.

147. van der Bogt RD, van der Wilk BJ, Oudijk L, Schoon EJ, van Lijnschoten G, Corporaal S, Nieken J, Siersema PD, Bisseling TM, van der Post RS, Quispel R, van Tilburg A, Oostenbrug LE, Riedl RG, Hol L, Kliffen M, Nikkessen S, Eyck BM, van Lanschot JJB, Doukas M, Spaander MCW. Bite-on-bite biopsies for the detection of residual esophageal cancer after neoadjuvant chemoradiotherapy. *Endoscopy*. 2022;54(12):1131-8.
148. van der Meulen MP, Toes-Zoutendijk E, Spaander MCW, Dekker E, Bonfrer JMG, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, van Velthuysen MF, Thomeer MGJ, van Veldhuizen H, de Koning HJ, Lansdorp-Vogelaar I, van Leerdam ME. Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing. *PLoS One*. 2022;17(2):e0264067.
149. van der Schoor AS, Severin JA, van der Weg AS, Strepis N, Klaassen CHW, van den Akker JPC, Bruno MJ, Hendriks JM, Vos MC, Voor In 't Holt AF. Correction: The effect of 100% single-occupancy rooms on acquisition of extended-spectrum beta-lactamase-producing Enterobacterales and intra-hospital patient transfers: a prospective before-and-after study. *Antimicrob Resist Infect Control*. 2022;11(1):162.
150. van Tilburg L, Brands MT, Koch AD. To screen or not to screen: Reply to "Long-term results of an endoscopic screening program for superficial esophageal cancer in patients with head and neck squamous cell carcinoma". *Endosc Int Open*. 2022 Oct 17;10(10):E1328-E1329.
151. van der Vlugt M, Carvalho B, Fliers J, Montazeri N, Rausch C, Grobbee EJ, van Engeland M, Spaander MCW, Meijer GA, Dekker E. Missed colorectal cancers in a fecal immunochemical test-based screening program: Molecular profiling of interval carcinomas. *World J Gastrointest Oncol*. 2022;14(11):2195-207.
152. van Hooff MC, Sonneveld MJ, Ijzermans JN, Doukas M, Sprengers D, Metselaar HJ, den Hoed CM, de Man RA. External Validation of the RETREAT Score for Prediction of Hepatocellular Carcinoma Recurrence after Liver Transplantation. *Cancers (Basel)*. 2022;14(3).
153. van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. *Hepatology*. 2022;75(2):419-29.
154. van Kleef LA, Hofman A, Voortman T, de Knegt RJ. Objectively Measured Physical Activity Is Inversely Associated With Nonalcoholic Fatty Liver Disease: The Rotterdam Study. *Am J Gastroenterol*. 2022 Feb 1;117(2):311-318.
155. Van Kleef LA, Ayada I, de Knegt RJ. Discrepancy Between NAFLD and MAFLD: Is it Only Due to Misclassification of MAFLD? *Clin Gastroenterol Hepatol*. 2022.
156. van Kleef LA, de Knegt RJ. Modifiable risk factors for fatty liver disease: Time to act. *Hepatology*. 2022.
157. van Kleef LA, de Knegt RJ. Reply to: "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD". *Hepatol Commun*. 2022;6(9):2605-6.
158. van Kleef LA, de Knegt RJ. The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach? *Hepatology*. 2022;76(5):1243-5.
159. van Kleef LA, de Knegt RJ, Brouwer WP. Metabolic dysfunction-associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality. *Hepatology*. 2022.
160. van Kleef LA, Kavousi M, de Knegt RJ. Reply to: "Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues". *J Hepatol*. 2022;77(5):1467-8.
161. van Kleef LA, Lu Z, Ikram MA, de Groot NMS, Kavousi M, de Knegt RJ. Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study. *J Hepatol*. 2022;77(4):931-8.

162. van Kleef LA, Sonneveld MJ, de Man RA, de Knecht RJ. Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline. *J Hepatol.* 2022;76(1):245-6.
163. van Linschoten RCA, van Leeuwen N, Nieboer D, Birnie E, Scherpenzeel M, Verweij KE, de Jonge V, Hazelzet JA, van der Woude CJ, West RL, van Noord D; Southwest Netherlands IBD Study Group. Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period. *BMJ Open.* 2022 Jan 12;12(1):e050539.
164. van Munster SN, Frederiks CN, Nieuwenhuis EA, Alvarez Herrero L, Bogte A, Alkhalaf A, Schenk BE, Schoon EJ, Curvers WL, Koch AD, van de Ven SEM, de Jonge PJF, Tang TJ, Nagengast WB, Peters FTM, Westerhof J, Houben MHMG, Bergman JJGHM, Pouw RE, Weusten BLAM. Incidence and outcomes of poor healing and poor squamous regeneration after radiofrequency ablation therapy for early Barrett's neoplasia. *Endoscopy.* 2022 Mar;54(3):229-240.
165. van Munster SN, Nieuwenhuis E, Bisschops R, Willekens H, Weusten BLAM, Herrero LA, Bogte A, Alkhalaf A, Schenk EBE, Schoon EJ, Curvers W, Koch AD, de Jonge PJF, Tang TJ, Nagengast WB, Westerhof J, Houben MHMG, Bergman JJGHM, Pouw RE. Development and External Validation of a Model to Predict Complex Treatment After Radiofrequency Ablation for Barrett's Esophagus With Early Neoplasia. *Clin Gastroenterol Hepatol.* 2022 Nov;20(11):2495-2504.e5.
166. van Munster SN, Nieuwenhuis E, Bisschops R, Willekens H, Weusten BLAM, Herrero LA, Bogte A, Alkhalaf A, Schenk EBE, Schoon EJ, Curvers W, Koch AD, de Jonge PJF, Tang TJ, Nagengast WB, Westerhof J, Houben MHMG, Seewald S, Eijkemans MJC, Bergman JJGHM, Pouw RE. Dysplastic Recurrence After Successful Treatment for Early Barrett's Neoplasia: Development and Validation of a Prediction Model. *Gastroenterology.* 2022 Jul;163(1):285-294.
167. van Munster S, Nieuwenhuis E, Weusten BLAM, Alvarez Herrero L, Bogte A, Alkhalaf A, Schenk BE, Schoon EJ, Curvers W, Koch AD, van de Ven SEM, de Jonge PJF, Tang TJ, Nagengast WB, Peters FTM, Westerhof J, Houben MHMG, Bergman JJ, Pouw RE; Dutch Barrett Expert Centers. Long-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period. *Gut.* 2022 Feb;71(2):265-276.
168. van Munster SN, Verheij EPD, Nieuwenhuis EA, Offerhaus JGJA, Meijer SL, Brosens LAA, Weusten BLAM, Alkhalaf A, Schenk EBE, Schoon EJ, Curvers WL, van Tilburg L, van de Ven SEM, Tang TJ, Nagengast WB, Houben MHMG, Seldenrijk KCA, Bergman JJGHM, Koch AD, Pouw RE; Dutch Barrett Expert Centers. Extending treatment criteria for Barrett's neoplasia: results of a nationwide cohort of 138 endoscopic submucosal dissection procedures. *Endoscopy.* 2022 Jun;54(6):531-541.
169. van der Ploeg K, Bruno MJ. Gastrointestinal Endoscopy-Associated Infections: We Need to Be Specific. *Dig Dis Sci.* 2022 Aug;67(8):4261-4262.
170. van der Wiel SE, Stassen PMC, Poley JW, De Jong DM, de Jonge PJF, Bruno MJ. Pancreatoscopy-guided electrohydraulic lithotripsy for the treatment of obstructive pancreatic duct stones: a prospective consecutive case series. *Gastrointest Endosc.* 2022 May;95(5):905-914.e2.

171. van Tilburg L, van de Ven SEM, Spaander MCW, van Kleef LA, Cornelissen R, Bruno MJ, Koch AD. Prevalence of lung tumors in patients with esophageal squamous cell carcinoma and vice versa: a systematic review and meta-analysis. *J Cancer Res Clin Oncol*. 2022.
172. van Tilburg L, van den Ban SA, van de Ven SEM, Sewnaik A, Bruno MJ, Spaander MCW, Baatenburg de Jong RJ, Koch AD. Screening for head and neck tumors in patients with esophageal squamous cell carcinoma and vice versa: a nationwide survey among medical specialists. *Endosc Int Open*. 2022;10(9):E1268-E74.
173. van Tilburg L, Brands MT, Koch AD. To screen or not to screen: Reply to "Long-term results of an endoscopic screening program for superficial esophageal cancer in patients with head and neck squamous cell carcinoma". *Endosc Int Open*. 2022;10(10):E1328-E9.
174. van Tilburg L, van den Ban SA, van de Ven SEM, Sewnaik A, Bruno MJ, Spaander MCW, Baatenburg de Jong RJ, Koch AD. Screening for head and neck tumors in patients with esophageal squamous cell carcinoma and vice versa: a nationwide survey among medical specialists. *Endosc Int Open*. 2022;10(9):E1268-E74.
175. van Toledo D, JEG IJ, Bossuyt PMM, Bleijenberg AGC, van Leerdam ME, van der Vlugt M, Lansdorp-Vogelaar I, Spaander MCW, Dekker E. Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study. *Lancet Gastroenterol Hepatol*. 2022;7(8):747-54.
176. van Veldhuisen CL, Latenstein AEJ, Blauw H, Vlaskamp LB, Klaassen M, Lips DJ, Bonsing BA, van der Harst E, Stommel MWJ, Bruno MJ, van Santvoort HC, van Eijck CHJ, van Dieren S, Busch OR, Besselink MG, DeVries JH, Dutch Pancreatic Cancer G. Bihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy: A Randomized Clinical Trial. *JAMA Surg*. 2022;157(10):950-7.
177. Visser IJ, Levink IJM, Peppelenbosch MP, Fuhler GM, Bruno MJ, Cahen DL. **Systematic review and meta-analysis: Diagnostic performance of DNA alterations in pancreatic juice for the detection of pancreatic cancer.** *Pancreatology*. 2022 Nov;22(7):973-986.
178. Vuik FER, Moen S, Spaander MCW. Colon capsule endoscopy as panendoscopy: Using current knowledge to enhance possibilities. *Endosc Int Open*. 2022;10(5):E584.
179. Vuik FER, Nieuwenburg SAV, Moen S, Schreuders EH, Oudkerk Pool MD, Peterse EFP, Spada C, Epstein O, Fernandez-Urien I, Hofman A, Kuipers EJ, Spaander MCW. Population-Based Prevalence of Gastrointestinal Abnormalities at Colon Capsule Endoscopy. *Clin Gastroenterol Hepatol*. 2022;20(3):692-700 e7.
180. Wisse PHA, de Klaver W, van Wifferen F, Meiqari L, Bierkens M, Greuter MJE, Carvalho B, van Leerdam ME, Spaander MCW, Dekker E, Coupe VMH, de Wit M, Meijer GA. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design. *BMC Cancer*. 2022;22(1):1299.
181. Wisse PHA, Erler NS, de Boer SY, den Hartog B, Oudkerk Pool M, Terhaar Sive Droste JS, Verveer C, Meijer GA, Lansdorp-Vogelaar I, Kuipers EJ, Dekker E, Spaander MCW. Adenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test-Based Screening : A Population-Based Cohort Study. *Ann Intern Med*. 2022;175(10):1366-73.
182. Ykema BLM, Gini A, Rigter LS, Spaander MCW, Moons LMG, Bisseling TM, de Boer JP, Verbeek WHM, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, van der Maazen RWM, group Ds, Aleman BMP, Meijer GA, van Leeuwen FE, Snaebjornsson P, Carvalho B, van Leerdam ME, Lansdorp-Vogelaar I. Cost-Effectiveness of Colorectal Cancer

- Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy. *Cancer Epidemiol Biomarkers Prev.* 2022;31(12):2157-68.
183. Ykema BLM, Rigter LS, Spaander MCW, Moons LMG, Bisseling TM, Aleman BMP, Dekker E, Verbeek WHM, Kuipers EJ, de Boer JP, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, van der Maazen RWM, Meijer GA, Schaapveld M, van Leeuwen FE, Carvalho B, Snaebjornsson P, van Leerdam ME. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors. *Dig Endosc.* 2022;34(1):163-70.
184. Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, Gadano A, Popescu CP, Stepanova T, Asselah T, Diaconescu G, Yim HJ, Heo J, Janczewska E, Wong A, Idriz N, Imamura M, Rizzardini G, Takaguchi K, Andreone P, Arbune M, Hou J, Park SJ, Vata A, Cremer J, Elston R, Lukic T, Quinn G, Maynard L, Kendrick S, Plein H, Campbell F, Paff M, Theodore D, Group BCS. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. *N Engl J Med.* 2022;387(21):1957-68.
185. Zellenrath PA, Roumans CAM, Spaander MCW. Today's Mistakes and Tomorrow's Wisdom... In Barrett's Surveillance. *Visc Med.* 2022;38(3):168-72.
186. Zhang X, Mou Y, Aribas E, Amiri M, Nano J, Bramer WM, Kavousi M, de Knecht RJ, Asllanaj E, Ghanbari M. Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis. *Genes (Basel).* 2022;13(6).
187. **Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. *Br J Cancer.* 2022 Jan;126(1):10-23.**
188. Zoulim F, Zlotnick A, Buchholz S, Donaldson E, Fry J, Gaggar A, Hu J, Kann M, Lenz O, Lin K, Mani N, Nassal M, Delaney W, Wang S, Westman G, Miller V, Janssen HLA. Nomenclature of HBV core protein-targeting antivirals. *Nat Rev Gastroenterol Hepatol.* 2022;19(12):748-50.

B Promotions in 2022

- 24-02-2022. Ruben Hoogeveen. A war of exhaustion. T cell signatures in hepatitis B virus infection. Supervisors: H.J. Metselaar. Cosupervisors: A. Boonstra, G. Lauer.
- 24-02-2022. Seng Liem. Optimizing Antiviral Therapy for Chronic Hepatitis B. A controlled shift towards cure. Supervisors: R.A. de Man, H.L.A. Janssen. Cosupervisor: B.E. Hansen.
- 22-03-2022. Gulce Sari. Innate Immune Responses in Hepatitis E Virus Infections. Awaken the force within. Supervisors: R.A. de Man, A. Boonstra. Cosupervisor: T. Vanwollegem.
- 06-04-2022. Rutger Quispel. Exploring Quality of Endoscopic Ultrasonography in Clinical Practice. Supervisor: M.J. Bruno. Cosupervisors: L.M.J.W. van Driel, B.J. Veldt.
- 31-05-2022. Sophia van der Wiel. Optimizing performance and techniques in advanced pancreatobiliary endoscopy. Supervisor: M.J. Bruno. Cosupervisor: A.D. Koch.
- 24-06-2022. Stella Nieuwenburg. Screening and surveillance of the gastrointestinal tract. Supervisors: M.C.W. Spaander, E.J. Kuipers.
- 29-06-2022. Evelien Beelen. Postoperative Recurrence of Crohn's Disease after Ileocolonic Resection: Epidemiology, prediction and prevention. Supervisor: C.J. van der Woude. Cosupervisor: A.C. de Vries.
- 14-09-2022. Chantal ten Kate. It doesn't end with closure. Optimizing health care throughout life after esophageal atresia repair. Supervisors: T.M. Wijnen, M.C.W. Spaander. Cosupervisors: H. IJsselstijn, E. Brosens.
- 27-09-2022. Rachid Bouzid. Discovering Drugable Immune Targets in Gastrointestinal & Hepatic Disease. Supervisors: M.J. Bruno, M. Peppelenbosch. Cosupervisor: S. Buschow.
- 05-10-2022. Monique de Beijer Antigeenpresentatie in Hepatitis B-virusinfectie en hepatocellulair carcinoom. Towards rational development of antigen-specific immunotherapy. Supervisor: R.A. de Man. Cosupervisors: A.M. Woltman, S. Buschow.
- 16-11-2022. Noé Rico Montanari. Immune and transcriptomic profiling of distinct hepatitis B disease states. Supervisor: A. Boonstra. Cosupervisor: J. Debes.
- 02-12-2022. Fanny Vuik. The gastrointestinal tract: From healthy mucosa to colorectal cancer. Supervisor: M.C.W. Spaander

C Events organized in 2022

24-11-2022. 37th Erasmus Liver Day, congress center de Doelen, Rotterdam.